Puberty Blockers Clinical Trial
Debate between Jonathan Hinder and Rachel Taylor(2 weeks, 3 days ago)
Westminster HallRead Full debate Read Hansard Text Read Debate Ministerial Extracts
Westminster Hall is an alternative Chamber for MPs to hold debates, named after the adjoining Westminster Hall.
Each debate is chaired by an MP from the Panel of Chairs, rather than the Speaker or Deputy Speaker. A Government Minister will give the final speech, and no votes may be called on the debate topic.
This information is provided by Parallel Parliament and does not comprise part of the offical record
Rachel Taylor (North Warwickshire and Bedworth) (Lab)
It is a pleasure to serve under your chairmanship, Mr Mundell. Over the past year, the public debate has become often heated and personal and, at times, deeply harmful. The rhetoric has consequences, and we in this House must take responsibility for the climate that we help to create.
The Cass review’s recommendations were so important, and among them was a clear call for carefully designed clinical trials to build the evidence base around puberty blockers. Those trials would allow clinicians, patients and families to make informed decisions grounded in robust data rather than speculation or ideology. Those who argued that puberty blockers should be restricted due to insufficient evidence are now opposing the very research that would provide that evidence. That does not suggest a commitment to scientific rigour; it suggests a shifting position driven by political ideology. I am not a clinician, and I do not pretend to be. On matters such as these, we must be guided by medical evidence.
Rachel Taylor
For the sake of time, I will not.
The need to be guided by evidence is precisely why the current situation is so troubling. It is concerning that the MHRA initially raised no objections to the trial when it was approved but has since changed that position. As Dr Cass made clear, no new evidence has been presented to justify that shift. That raises serious questions about the basis of the decision, and whether an independent regulator has buckled to pressure from a well-funded lobbying campaign. As a consequence, vital research is now at risk, and that matters. The trials are not an optional extra; they are the mechanism through which we build the evidence base that critics say is lacking.